ACE2 and COVID-19: The largest of the six study clusters discussed is COVID-19, where evidence has emerged that SARS-CoV-2 infecting Angiotensin-converting enzyme 2 (ACE2) leads to olfactory impairment in patients with neocoronary pneumonia (Bilinska et al., 2020).